Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Moody's Corporation (MCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Moody's Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $279.67 (market cap $39.89B), while Moody's Corporation trades at $494.86 (market cap $85.12B). The key difference: Moody's Corporation is far larger — about 2.1× Alnylam Pharmaceuticals, Inc.'s market cap, and Moody's Corporation pays a 0.85% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | MCO | |
|---|---|---|
Market Cap | $39.89B | $85.12B |
Sector | Health | Financials |
52-Week High | $491.22 | $539.61 |
52-Week Low | $278.09 | $412.23 |
Enterprise Value | $38.15B | $90.92B |
Dividend Yield | — | 0.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
MCO trades at $487.28, up 0.05% on the day, with a bullish technical signal supported by moving averages and strong fundamentals. The company reported Q1 2026 EPS of $4.33, beating estimates, and maintains robust profitability with a 31.69% net income margin. Recent news highlights Moody's AI initiatives, including new AI skills and integrations, positioning for growth in credit analytics. The stock is near its 52-week high, with support at $481 and resistance at $490.
Outlook remains positive with a consensus price target of $539.40, implying 11% upside, driven by earnings momentum and AI adoption. Risks include high valuation multiples (P/E 34.96) and dependence on debt issuance cycles. Institutional sentiment is bullish with 56% buy ratings, but overbought RSI levels suggest near-term consolidation potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →
